NEUP
Neuphoria Therapeutics Inc.NASDAQHealthcare$4.41-2.04%ClosedMarket Cap: $8.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.66
P/S
0.99
EV/EBITDA
0.02
DCF Value
$85.19
FCF Yield
920.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.7%
Operating Margin
-13713.7%
Net Margin
-4546.6%
ROE
-1538.3%
ROA
-1020.1%
ROIC
-1466.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | -Infinity% | $-2.8M | $1.9M | $-0.77 | — |
| Q1 2026 | $0.00 | -Infinity% | $-8.6M | $-15.0M | $-6.67 | — |
| Q4 2025 | $-15.7M | 97.9% | $-1.13B | $-378.1M | $-6.77 | — |
| FY 2025 | $24.0M | 95.8% | $-1.7M | $-565.8K | $-0.23 | — |
| Q3 2025 | $23.9M | 98.9% | $19.1M | $17.9M | $6.55 | — |
| Q2 2025 | $1.1M | 0.0% | $-6.0M | $-3.1M | $-0.01 | — |
| Q1 2025 | $0.00 | -Infinity% | $-5.2M | $-1.2M | $-0.00 | — |
| Q4 2024 | $0.00 | -Infinity% | $-8.2M | $-4.0M | $-29.21 | — |
| FY 2024 | $0.00 | -Infinity% | $-26.8M | $-23.2M | $-0.10 | — |
| Q3 2024 | $0.00 | -Infinity% | $-3.7M | $-4.3M | $-0.02 | — |
| Q2 2024 | $0.00 | NaN% | $-6.7M | $-6.7M | $-0.03 | — |
| Q1 2024 | $0.00 | -Infinity% | $-5.2M | $-1.2M | $-0.04 | — |